Genetic and genomic predictors of anti-TNF response (Q37951648)

25 August 2017

title

Genetic and genomic predictors of anti-TNF response (English)

1 reference

25 August 2017

0 references

0 references

3

1 reference

25 August 2017

Rita Prajapati

1

1 reference

25 August 2017

Darren Plant

series ordinal

2

1 reference

25 August 2017

publication date

1 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1571-1585

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

TNF pathophysiology in murine models of chronic inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

CD45: a critical regulator of signaling thresholds in immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF B signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.114

21 January 2018

Identifiers

DOI

10.2217/PGS.11.114

1 reference

25 August 2017

1 reference